Phase I-II study of docetaxel and ifosfamide combination in patients with anthracycline pretreated advanced breast cancer

British Journal of Cancer

Volumn 88, Issue 8, 2003, Pages 1168-1174

  Kosmas, C ^a   Tsavaris, N ^b   Malamos, N ^a   Stavroyianni, N ^b   Gregoriou, A ^a   Rokana, S ^a   Polyzos, A ^b  

^a HELENA VENIZELOU HOSPITAL   (Greece)

^b UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

Author keywords

Breast cancer; Docetaxel; Ifosfamide; Phase I study

Indexed keywords

ANTHRACYCLINE; ANTIBIOTIC AGENT; ANTIEMETIC AGENT; DEXAMETHASONE; DIMETINDENE; DOCETAXEL; FUROSEMIDE; IFOSFAMIDE; MESNA; METHYLPREDNISOLONE; ONDANSETRON; RANITIDINE; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; STEROID;

ADULT; ADVANCED CANCER; AGED; ALOPECIA; ANEMIA; ARTHRALGIA; ARTICLE; ASTHENIA; BRAIN DISEASE; BRAIN METASTASIS; BREAST CANCER; BREAST METASTASIS; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER REGRESSION; CANCER SURVIVAL; CARDIOTOXICITY; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DELIRIUM TREMENS; DIARRHEA; DOSE RESPONSE; DRUG ACTIVITY; DRUG DOSE REGIMEN; FATIGUE; FEASIBILITY STUDY; FEBRILE NEUTROPENIA; FEMALE; FLUID RETENTION; HEMATURIA; HUMAN; HYPERSENSITIVITY REACTION; LEUKOPENIA; LIVER FAILURE; LUNG TOXICITY; MAJOR CLINICAL STUDY; MAXIMUM TOLERATED DOSE; METABOLIC ACIDOSIS; MORTALITY; MUCOSA INFLAMMATION; MYALGIA; NAIL DISEASE; NAUSEA; NEPHROTOXICITY; NEUROTOXICITY; NEUTROPENIA; PERIPHERAL NEUROPATHY; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROPHYLAXIS; SEPSIS; SKIN TOXICITY; STATISTICAL ANALYSIS; THROMBOCYTOPENIA; TREATMENT INDICATION; TREATMENT OUTCOME; VOMITING;

ADULT; AGED; ANTHRACYCLINES; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; IFOSFAMIDE; INFUSIONS, INTRAVENOUS; MIDDLE AGED; SURVIVAL ANALYSIS; TAXOIDS; TREATMENT FAILURE;

EID: 0037809467     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bjc.6600887     Document Type: Article

References (33)

1. Ahmann DI, Bisel HF, Hahn RG (1974) Phase II clinical trial of isophosphamide (NSC-109724) in patients with advanced breast cancer. Cancer Chemother Rep 58: 861-865
2. Bitran JD, Samuels BL, Marsik S, Gambino A, White L (1995) A phase I study of ifosfamide and doxorubicin with recombinant human granulocyte colony-stimulating factor in stage IV breast cancer. Clin Cancer Res 1: 185-188
3. Bunnell CA, Thompson L, Buswell L, Berkowitz R, Muto M, Sheets E, Shulman LN (1998) A phase I trial of ifosfamide and paclitaxel with granulocyte-colony stimulating factor in the treatment of patients with refractory solid tumors. Cancer 82: 561-566
4. Cerny T, Leyvraz S, von Briel T, Kupfer A, Schaad R, Schmitz SF, Honegger P, Sessa C, Brunner J, Boddy AV (1999) Saturable metabolism of continuous high-dose ifosfamide with mesna and GM-CSF: a pharmacokinetic study in advanced sarcoma patients. Swiss Group for Clinical Cancer Research (SAKK). Ann Oncol 10: 1087-1094
5. Chan S, Friedrichs K, Noel D, Pinter T, Van Belle S, Vorobiof D, Duarte R, Gil M, Bodrogi I, Murray E, Yelle L, von Minckwitz G, Korec S, Simmonds P, Buzzi F, Gonzalez Mancha R, Richardson G, Walpole E, Ronzoni M, Murawsky M, Alakl M, Riva A (1999) Prospective randomised trial of docetaxel versus doxorubicin in patients with metastatic breast cancer. The 303 Study Group. J Clin Oncol 17: 2341-2354
6. Kaplan EL, Meier P (1959) Non-parametric estimation from incomplete observations. J Am Stat Assoc 53: 457-481
7. Kearns CM, Gianni L, Egorin MJ (1995) Paclitaxel pharmacokinetics and pharmacodynamics. Semin Oncol 22(Suppl 6): 16-23
8. Kennedy MJ, Zahurak ML, Donehower RC, Noe DA, Sartorius S, Chen TL, Bowling K, Rowinsky EK (1996) Phase I and pharmacologic study of sequences of paclitaxel and cyclophosphamide supported by granulocyte colony-stimulating factor in women with previously treated metastatic breast cancer. J Clin Oncol 14: 783-791
9. Klaassen U, Harstrick A, Schleucher N, Vanhoefer U, Schroder J, Wilke H, Seeber S (1996) Activity and schedule-dependent interactions of paclitaxel, etoposide and hydroperoxy-ifosfamide in cisplatin-sensitive and -refractory human ovarian carcinoma cell lines. Br J Cancer 74: 224-228
10. Kosmas C, Tsavaris NB, Makatsoris T, Onyenadum A, Stavroyianni N, Vadiaka M, Sepsas E, Dimitropoulos D, Rokana S, Kalofonos HP (2002) A phase I-II study of docetaxel-ifosfamide-cisplatin (DIP) combination chemotherapy regimen in advanced non-small cell lung cancer. Int J Cancer 98: 141-147
11. Kosmas C, Tsavaris NB, Malamos NA, Vadiaka M, Koufos C (2001) A phase II study of paclitaxel-ifosfamide-cisplatin (PIC) as second-line treatment in relapsed small-cell lung cancer. J Clin Oncol 19: 119-126
12. Kosmas C, Tsavaris NB, Polyzos A, Kalofonos HP, Sepsas E, Malamos NA, Vadiaka M, Dosios T, Antonopoulos MJ (2000b) A phase II study of paclitaxel-ifosfamide-cisplatin (PIC) combination in advanced non-small cell lung cancer. Cancer 89: 774-782
13. Kosmas C, Tsavaris NB, Polyzos A, Malamos NA, Katsikas M, Antonopoulos MJ (2000a) Phase I study of dose escalated paclitaxel, ifosfamide, and cisplatin (PIC) combination chemotherapy in advanced solid tumours. Br J Cancer 82: 300-307
14. Leone BA, Vallejo CT, Romero AO, Perez JE, Cuevas MA, Lacava JA, Sabatini CL, Dominguez ME, Rodriguez R, Barbieri MR, Ortiz EH, Salvadori MA, Acuna LA, Acuna JM, Langhi MJ, Amato S, Machiavelli MR (1996) Ifosfamide and vinorelbine as first-line chemotherapy for metastatic breast cancer. J Clin Oncol 11: 2993-2999
15. Liebmann J'E, Fisher J, Teague D (1994) Sequence dependence of paclitaxel (Taxol) combined with cisplatin or alkylators in human cancer cells. Oncol Res 6: 25-31
16. Lorusso V, Crucitta E, Sambiasi D, Attolico M, De Lena M (2000) Docetaxel plus ifosfamide in advanced breast cancer refractory to anthracyclines: a phase II study. Ann Oncol 11(Suppl 4): 36 (abstract 154)
17. Miller AB, Hoogstraten B, Staquet M, Winkler A (1981) Reporting results of cancer treatment. Cancer 47: 207-214
18. Monnier A, Bonneterre J, Roche H, Fargeot P, Namer M, Guastalla JP, Rios M, Serin D, Culine S, Tubiana M (1998) Phase III study: taxotere (TXT) versus 5-fluorouracil+navelbine (FUN) in patients (pts) with metastatic breast cancer (MBC) as 2nd line chemotherapy. Ann Oncol 9(Suppl 4): 12 (abstract 58O)
19. Nabholtz JM, Senn HJ, Bezwoda WR, Melnychuk D, Deschenes L, Douma J, Vandenberg TA, Rapoport B, Rosso R, Trillet-Lenoir V, Drbal J, Molino A, Nortier JW, Richel DJ, Nagykalnai T, Siedlecki P, Wilking N, Genot JY, Hupperets PS, Pannuti F, Skarlos D, Tomiak EM, Murawsky M, Alakl M, Aapro M, for the 304 Study Group (1999) Prospective randomised trial of docetaxel versus mitomycin plus vinblastine in patients with metastatic breast cancer progressing despite previous anthracycline-containing chemotherapy. 304 Study Group. J Clin Oncol 17: 1413-1424
20. O'Shaughnessy J, Miles D, Vukelja S, Moiseyenko V, Ayoub J-P, Cervantes G, Fumoleau P, Jones S, Lui W-Y, Mauriac L, Twelves C, Van Hazel G, Verma S, Leonard R (2002) Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: phase III trial results. J Clin Oncol 20: 2812-2823
21. Pagani O, Sessa C, Martinelli G, Cerny T, de Jong J, Goldhirsch A, Zimatore M, Cavalli F (1997) Dose-finding study of paclitaxel and cyclophosphamide in advanced breast cancer. Ann Oncol 8: 655-661
22. Paridaens R, Biganzoli L, Bruning P, Klijn JG, Gamucci T, Houston S, Coleman R, Schachter J, Van Vreckem A, Sylvester R, Awada A, Wildiers J, Piccart M (2000) Paclitaxel versus doxorubicin as first-line single-agent chemotherapy for metastatic breast cancer: a European Organization for Research and Treatment of Cancer Randomised Study with cross-over. J Clin Oncol 18: 724-733
23. Pronk LC, Schrijvers D, Schellens JH, de Bruijn EA, Planting AS, Locci-Tonelli D, Groult V, Verweij J, van Oosterom AT (1998) Phase I study on docetaxeI and ifosfamide in patients with advanced solid tumours. Br J Cancer 77: 153-158
24. Ravdin PM, Burris III HA, Cook G, Eisenberg P, Kane M, Bierman WA, Mortimer J, Genevois E, Bellet RE (1995) Phase II trial of docetaxel in advanced anthracycline-resistant or anthracenedione-resistant breast cancer. J Clin Oncol 13: 2879-2885
25. Reed E, Kohn EC, Sarosy G, Dabholkar M, Davis P, Jacob J, Maher M (1995) Paclitaxel, cisplatin, and cyclophosphamide in human ovarian cancer: molecular rationale and early clinical results. Semin Oncol 22(Suppl 6): 90-96
26. 2 is effective but not feasible for some metastatic breast cancer patients heavily pretreated with chemotherapy-A phase II single-center study. J Clin Oncol 17: 1127-1131
27. Schrijvers D, Pronk L, Highley M, Bruno R, Locci-Tonelli D, De Bruijn E, Van Oosterom AT, Verweij J (2000) Pharmacokinetics of ifosfamide are changed by combination with docetaxel: results of a phase I pharmacologic study. Am J Clin Oncol 23: 358-363
28. Simon R (1986) Confidence interval for reporting results of clinical trials. Ann Intern Med 105: 429-435
29. Simon R (1989) Optimal two-stage designs for phase II clinical trials. Control Clin Trials 10: 1-10
30. Sjostrom J, Blomqvist C, Mouridsen H, Pluzanska A, Ottosson-Lonn S, Bengtsson NO, Ostenstad B, Mjaaland I, Palm-Sjovall M, Wist E, Valvere V, Anderson H, Bergh J (1999) Docetaxel compared with sequential methotrexate and 5-fluorouracil in patients with advanced breast cancer after anthracycline failure: a randomised phase III study with cross over on progression by the Scandinavian Breast Group. Eur J Cancer 35: 1194-1201
31. Sledge Jr GW, Neuberg D, Ingle J, Martino S, Wood W (1997) Phase III trial of doxorubicin (A) vs. paclitaxel (T) vs. doxorubicin+paclitaxel (A+T) as first-line therapy for metastatic breast cancer (MBC): an intergroup trial. Proc Am Soc Clin Oncol 16: 1a (abstract 2)
32. Tolcher AW, Cowan KH, Noone MH, Denicoff AM, Kohler DR, Goldspiel BR, Barnes CS, McCabe M, Gossard MR, Zujewski J, O'Shaughnessy JA (1996) Phase I study of paclitaxel in combination with cyclophosphamide and granulocyte colony-stimulating factor in metastatic breast cancer patients. J Clin Oncol 14: 95-102
33. Valero V, Holmes FA, Walters RS, Theriault RL, Esparza L, Fraschini G, Fonseca GA, Bellet RE, Buzdar AU, Hortobagyi GN (1995) Phase II trial of docetaxel: a new, highly effective antineoplastic agent in the management of patients with anthracycIine-resistant metastatic breast cancer. J Clin Oncol 13: 2886-2894